STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’
- 1 April 2002
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 16 (4) , 570-572
- https://doi.org/10.1038/sj.leu.2402409
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 18 references indexed in Scilit:
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- New-age drug meets resistanceNature, 2001
- Why Some Leukemia Cells Resist STI-571Science, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of diseaseBritish Journal of Haematology, 2001
- Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cellsOncogene, 2000
- Telomere Dynamics and Genetic Instability in Disease Progression of Chronic Myeloid LeukemiaLeukemia & Lymphoma, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- Genetic instabilities in human cancersNature, 1998